Trial · NCT07904689
A Study of NOR-101 in Healthy Adults and Adults With Moderate-to-Severe Atopic Dermatitis
NCT07904689, Phase 1, Not yet recruiting, North Immunology Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of NOR-101 in Healthy Adults and Adults With Moderate-to-Severe Atopic Dermatitis. Trials, record NCT07904689. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07904689
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of NOR-101 in Healthy Adults and Adults With Moderate-to-Severe Atopic Dermatitis
- NCT number
- NCT07904689
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 96 participants, estimated
- Lead sponsor
- North Immunology Inc.
- Conditions
- Atopic Dermatitis (AD)
- Interventions
- NOR-101, Placebo
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with adverse events | From informed consent through the end of the trial (EOT), up to approximately 29 months. | Number of participants with adverse events, including serious adverse events, summarized by severity and relationship to study intervention in Parts 1 and 2. |
| Primary | Number of participants with clinically significant vital sign abnormalities | Baseline through 12 months after the last dose (up to approximately 20 months). | Number of participants with clinically significant vital sign abnormalities, as assessed by the investigator, in Parts 1 and 2. |
| Primary | Number of participants with clinically significant electrocardiogram abnormalities | Baseline through 12 months after the last dose (up to approximately 20 months). | Number of participants with clinically significant abnormalities on 12-lead electrocardiograms, as assessed by the investigator, in Parts 1 and 2. |
| Primary | Number of participants with clinically significant clinical laboratory abnormalities | Baseline through 12 months after the last dose (up to approximately 20 months). | Number of participants with clinically significant hematology, serum chemistry, coagulation or urinalysis abnormalities, as assessed by the investigator, in Parts 1 and 2. |
| Secondary | Maximum serum NOR-101 concentration (Cmax) | First dose through up to approximately 20 months after the last dose (up to approximately 28 months). | Maximum observed concentration in Part 1 and in Part 2. |
| Secondary | Area under the NOR-101 serum concentration-time curve (AUC) | First dose through up to approximately 20 months after the last dose (up to approximately 28 months). | AUC from dosing to the last quantifiable concentration after single dosing, and over the dosing interval after repeated dosing, in Part 1. AUC following multiple dosing in Part 2. |
| Secondary | NOR-101 terminal elimination half-life | First dose through up to approximately 20 months after the last dose (up to approximately 28 months). | Terminal half-life after single or repeated dosing in Part 1, where reliably estimable. |
| Secondary | Incidence of anti-NOR-101 antibodies | First dose through up to approximately 20 months after the last dose (up to approximately 28 months). | Participants with anti-drug antibodies in Parts 1 and 2. |
| Secondary | NOR-101 time to maximum serum concentration (Tmax) | First dose through up to approximately 20 months after the last dose (up to approximately 28 months). | Time to maximum observed serum concentration after single and repeated dosing in Part 1. |
| Secondary | NOR-101 apparent clearance (CL/F) | First dose through up to approximately 20 months after the last dose (up to approximately 28 months). | Apparent serum clearance after single and repeated dosing in Part 1, where reliably estimable. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07904689
GET https://conductscience.org/api/trials/v1/NCT07904689/registered